December 2021

As the most common trigeminal autonomic cephalalgia, this unilateral and severe headache is accompanied by ipsilateral autonomic features and is often challenging to treat.

A practical approach to initiating and tapering corticosteroids, and the considerations in the selection and monitoring parameters of steroid-sparing agents are crucial to the care of myasthenia gravis.

After years of research showing that it demonstrates similar benefit to alteplase, tenecteplase’s benefit in a large patient cohort with acute ischemic stroke will be tested in the TIMELESS trial.

An expert neurologist, advocacy director, and a pair of patients with NMOSD discuss the current landscape of the demyelinating disorder.

As Dravet syndrome is often nonresponsive to existing therapeutics, it can be a challenge to treat, and this refractory nature creates a great need for novel, innovative, and safe antiepileptic drugs for its treatment.

The diagnosis of Parkinson disease may seem straightforward at first, requiring neurologists to rely on their eyes and hands, but the treatment process can present challenges for both physicians and patients.

Data further investigated the impact of how individual disease-modifying therapies affect outcomes for this patient population.

All told, 48% of patients with MS reported that their most common primary person for guidance on cannabis use in MS was themself or no one, followed by a dispensary professional and MS physician.

Investigators provided 4 strategies for health care providers to implement when speaking to patients with MS, in an effort to improve communication between both parties.

Real-world data from a single-center study with more than 4 years of follow-up showed similar rates of moderate infections and malignancies to the general population with multiple sclerosis.

The results demonstrate a positive change in patients with previous disease-modifying drug failures.

Patient data were evaluated over a 3-year period, with analyses from baseline, year 1, and year 2 presented at previous CMSC meetings.

Both diets resulted in patients with MS reporting significant changes on Perceived Deficits Questionnaire scores for fatigue and cognitive dysfunction after 12 weeks of intervention.